Published in Obesity and Diabetes Week, March 22nd, 2004
This double-blind, placebo-controlled, single-dose, dose-escalation trial is planned to enroll 54 healthy, overweight volunteers. The study will evaluate the safety, tolerability and pharmacokinetic profile of APD356.
The single-dose protocol should be completed in the first half of this year and, if the results support further testing, Arena expects to begin a larger, multi-dose trial later this year to study the safety of multiple doses of APD356 and to examine weight loss in a double-blind,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week